Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome

  1. Frank L van de Veerdonk  Is a corresponding author
  2. Mihai G Netea
  3. Marcel van Deuren
  4. Jos WM van der Meer
  5. Quirijn de Mast
  6. Roger J Brüggemann
  7. Hans van der Hoeven
  1. Radboud University Medical Center, Netherlands
  2. Radboud University Medical Centre, Netherlands

Abstract

COVID-19 patients can present with pulmonary edema early in disease. We propose that the this is due to a local vascular problem because of activation of bradykinin 1 receptor (B1R) and B2R on endothelial cells in the lungs. SARS-CoV-2 enters the cell via ACE2 that next to its role in RAS is needed to inactivate des-Arg9 bradykinin, the potent ligand of the bradykinin receptor type 1 (B1). Without ACE2 acting as a guardian to inactivate the ligands of B1, the lung environment is prone for local vascular leakage leading to angioedema. Here we hypothesize that a bradykinin-dependent local lung angioedema via B1 and B2 receptors is an important feature of COVID-19. We propose that blocking the B2 receptor and inhibiting kallikrein activity might have an ameliorating effect on early disease caused by COVID-19 and might prevent acute respiratory distress syndrome (ARDS). In addition, this pathway might indirectly be responsive to anti-inflammatory agents.

Data availability

There are no datasets associated with this work.

Article and author information

Author details

  1. Frank L van de Veerdonk

    Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands
    For correspondence
    frank.vandeveerdonk@radboudumc.nl
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1121-4894
  2. Mihai G Netea

    Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands
    Competing interests
    No competing interests declared.
  3. Marcel van Deuren

    Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands
    Competing interests
    No competing interests declared.
  4. Jos WM van der Meer

    Internal Medicine, Radboud University Medical Centre, Nijmegen, Netherlands
    Competing interests
    Jos WM van der Meer, Senior editor, eLife.
  5. Quirijn de Mast

    Department of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands
    Competing interests
    No competing interests declared.
  6. Roger J Brüggemann

    Department of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands
    Competing interests
    No competing interests declared.
  7. Hans van der Hoeven

    Department of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands
    Competing interests
    No competing interests declared.

Funding

No external funding was received for this work.

Reviewing Editor

  1. Zsolt Molnár, University of Pécs, Medical School, Hungary

Version history

  1. Received: April 9, 2020
  2. Accepted: April 26, 2020
  3. Accepted Manuscript published: April 27, 2020 (version 1)
  4. Version of Record published: May 11, 2020 (version 2)

Copyright

© 2020, van de Veerdonk et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 9,784
    views
  • 1,431
    downloads
  • 212
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Frank L van de Veerdonk
  2. Mihai G Netea
  3. Marcel van Deuren
  4. Jos WM van der Meer
  5. Quirijn de Mast
  6. Roger J Brüggemann
  7. Hans van der Hoeven
(2020)
Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome
eLife 9:e57555.
https://doi.org/10.7554/eLife.57555

Share this article

https://doi.org/10.7554/eLife.57555

Further reading

    1. Medicine
    2. Microbiology and Infectious Disease
    3. Epidemiology and Global Health
    4. Immunology and Inflammation
    Edited by Jos WM van der Meer et al.
    Collection

    eLife has published articles on a wide range of infectious diseases, including COVID-19, influenza, tuberculosis, HIV/AIDS, malaria and typhoid fever.

    1. Medicine
    2. Neuroscience
    Yunlu Xue, Yimin Zhou, Constance L Cepko
    Research Advance

    Retinitis pigmentosa (RP) is an inherited retinal disease in which there is a loss of cone-mediated daylight vision. As there are >100 disease genes, our goal is to preserve cone vision in a disease gene-agnostic manner. Previously we showed that overexpressing TXNIP, an α-arrestin protein, prolonged cone vision in RP mouse models, using an AAV to express it only in cones. Here, we expressed different alleles of Txnip in the retinal pigmented epithelium (RPE), a support layer for cones. Our goal was to learn more of TXNIP’s structure-function relationships for cone survival, as well as determine the optimal cell type expression pattern for cone survival. The C-terminal half of TXNIP was found to be sufficient to remove GLUT1 from the cell surface, and improved RP cone survival, when expressed in the RPE, but not in cones. Knock-down of HSP90AB1, a TXNIP-interactor which regulates metabolism, improved the survival of cones alone and was additive for cone survival when combined with TXNIP. From these and other results, it is likely that TXNIP interacts with several proteins in the RPE to indirectly support cone survival, with some of these interactions different from those that lead to cone survival when expressed only in cones.